Article
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2023
Goodman Rachel S, Di Guardo Lorenza, Maurichi Andrea, Kirwin Brendan, Khattak Adnan, Vanella Vito, Lee Joanna, Lawless Aleigha, Czapla Juliane, Spagnoletti Andrea, Ambrosini Margherita, Livingstone Elisabeth, Long Georgina V, Sullivan Ryan J, Carlino Matteo S, Atkinson Victoria, Trojanello Claudia, Ascierto Paolo A, Schadendorf Dirk, Warburton Lydia, Menzies Alexander M, Santinami Mario, Johnson Douglas B
Abstract excerpt
BACKGROUND: Recent studies have shown that approximately 20% of patients have 4-5 year progression free survival (PFS) on BRAF/MEK inhibitors. The long-term safety and efficacy in these patients with more durable responses have not been studied. METHODS: This retrospective multicenter cohort study assessed response, progression, and adverse events in patients from eight institutions in four countries with >4-year...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.